Navigation Links
Waters Introduces Ostro Sample Preparation Products
Date:9/14/2010

MILFORD, Mass., Sept. 14 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today introduced the new Ostro™ Sample Preparation Plate, representing a novel approach for the removal of phospholipids from biological samples. When compared to other phospholipid removal devices and traditional liquid-liquid extraction (LLE) methods, Ostro removes up to 30 times more phospholipids.

Phospholipids have been cited as a major cause of matrix effects in the LC/MS analysis of biological samples. Ostro, with its proprietary, patent-pending design, was specifically created to overcome this hurdle by offering a "best-in-class" solution that removes multiple families of phospholipids.

The Ostro 96-well plate format utilizes in-well protein precipitation with a single, rapid, pass-through method that provides a quick, reliable, and reproducible solution.

"We are excited and proud to introduce Ostro as an extension of our comprehensive family of 96-well sample preparation plates," comments Dr. Diane Diehl, Director, Sample Preparation, Waters Division. "Ostro will be a valuable tool for researchers who are struggling with phospholipid interferences, and provide a complimentary solution to Oasis® SPE products -- Waters premier solid-phase extraction solution."

For more information on Waters® Ostro Sample Preparation Products:

Brochure:

http://www.waters.com/webassets/cms/library/docs/720003695en.pdf

Product information:

http://www.waters.com/waters/nav.htm?cid=10156075

About Waters Chemistry Products

Waters provides the industry's broadest and deepest product offering manufactured to industry benchmark quality requirements by a world-class manufacturing organization and supported by highly-skilled and trained support teams. Waters maintains one of the largest applications databases of its kind surpassing 60,000 individual citations, abstracts, applications notes and scientific articles.

About Waters Corporation (www.waters.com)

For more than 50 years, Waters Corporation creates business advantages for laboratory-dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, and water quality worldwide.

Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success.

With revenue of $1.5 billion in 2009 and 5,200 employees, Waters is driving scientific discovery and operational excellence for customers worldwide.

Waters, the Science of What's Possible, Oasis and Ostro are trademarks of Waters Corporation.


'/>"/>
SOURCE Waters Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard
2. New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals
3. Waters Corporation and NIBRT Partner to Bring Greater Control and Predictability to Biopharmaceutical Processing
4. Waters Expands Xevo MS Instrument Platform With Next-Generation Mass Spectrometers
5. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
6. Dr. Dello Russo Introduces the New EYE-Q Lasik
7. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
8. Wedgewood Introduces Refresh(TM) Exchange-Program: Free Exchange of Expired Veterinary Compounded Medications Solves Key Industry Problem
9. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
10. Thermo Fisher Scientific Introduces Breakthrough in RNA-Interference Technology
11. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Israel , December 5, 2016 ... identifying, in-licensing and developing promising therapeutic candidates, presents positive Phase ... BL-8040, the Company,s leading oncology platform at the ongoing 58th ... San Diego, California . ... , , ...
(Date:12/5/2016)... TAIPEI, Taiwan , Dec. 5, 2016 ... showed non-inferiority to hydroxyurea (HU) in Complete Hematologic Response (CHR) ... tolerability profile of ropeginterferon alfa-2b versus HU ... long-term follow-up trial CONTINUATION-PV to obtain European marketing authorization in ... this data to the FDA as it seeks approval for ...
(Date:12/4/2016)... HOUSTON , Dec. 3, 2016   Pairnomix, LLC, ... Precision Medicine Alliance (PEPMA) recognized by the White House, today ... individualized approach to the identification of candidate therapies for a ... SCN8A gene were presented at the 70 th ... in Houston, TX , December 2-6, 2016.  ...
Breaking Medicine Technology:
(Date:12/5/2016)... Diego, CA (PRWEB) , ... December 05, 2016 , ... ... seen and heard the dangers and downsides of patients who do not do their ... The field of cosmetic dermatology is in the midst of a renaissance and every ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Rejuvenation" at the 2016 Anti-Aging & Beauty Awards at The Aesthetic & ... & Anti-aging Medicine European Congress (AMEC) brings together the industry’s leading scientific ...
(Date:12/5/2016)... ... December 05, 2016 , ... A ... Patch® significantly improves the reproducibility and accuracy of placing precordial electrodes with little ... , Over the last 60 years, studies have shown that single electrode misplacement ...
(Date:12/4/2016)... ... 03, 2016 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... New York City, with long-time partners The Paul Foundation, on November 10, 2016. ...
(Date:12/4/2016)... , ... December 03, 2016 , ... While James Earl ... serving as host for in a show called "Front Page". One of the forthcoming ... years, breast cancer rates have plummeted in large part due to early detection. Like ...
Breaking Medicine News(10 mins):